NCT05075057 is a Phase 4 clinical trial of Inactivated COVID-19 vaccine in COVID-19, sponsored by China National Biotec Group Company Limited.

Who is sponsoring NCT05075057?

NCT05075057 is sponsored by China National Biotec Group Company Limited.

What drugs are being tested in NCT05075057?

Interventions in NCT05075057: Inactivated COVID-19 vaccine.

What condition does NCT05075057 study?

NCT05075057 studies COVID-19, Chronic Bronchitis, Copd.

Is NCT05075057 still recruiting?

NCT05075057 is currently status unknown. Last updated 22 October 2021.

Last reviewed 2021-10-22 · How we verify

NCT05075057

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD

Status unknown Phase 4 Last updated 22 October 2021

What this trial tests

Phase 4 trial testing Inactivated COVID-19 vaccine in COVID-19 in 400 participants. Status unknown.

Timeline

8 October 2021

Primary endpoint
30 June 2022

30 June 2022

Quick facts

Lead sponsor	China National Biotec Group Company Limited
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	400
Start date	8 October 2021
Primary completion	30 June 2022
Estimated completion	30 June 2022
Sites	1 location across China

Drugs / interventions tested

Inactivated COVID-19 vaccine — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
Chronic Bronchitis — all drugs for Chronic Bronchitis →
Copd — all drugs for Copd →

Sponsor

China National Biotec Group Company Limited — full company profile →

Who can join

60 and older, any sex, with COVID-19 or Chronic Bronchitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of immunogenicity and safety of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive the schedule of three doses of inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively .

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.
Al-Hatamleh MAI, Abusalah MA, Hatmal MM, Alshaer W, et al · · 2023 · cited 7× · PMID 36570799 · DOI 10.1016/j.jtumed.2022.11.007
Current clinical status of new COVID-19 vaccines and immunotherapy.
Nagpal D, Nagpal S, Kaushik D, Kathuria H. · · 2022 · cited 6× · PMID 36063274 · DOI 10.1007/s11356-022-22661-1

Verify or expand the search:

Other trials of Inactivated COVID-19 vaccine

Trials testing the same drug.

NCT05075044 — Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected · Phase 4 · unknown
NCT05075070 — Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected · Phase 4 · unknown
NCT05075083 — Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD · Phase 4 · unknown

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other China National Biotec Group Company Limited trials

Trials by the same sponsor.

NCT07338851 — the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines · not yet recruiting
NCT07377175 — Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. · Phase 1 · recruiting
NCT05839301 — A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age · Phase 3 · unknown
NCT05669625 — A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine · Phase 3 · active not recruiting
NCT05480436 — Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05075057 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China National Biotec Group Company Limited
Last refreshed: 22 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05075057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing